Research programme: COU-1 monoclonal antibodies - Affitech/NatImmune

Drug Profile

Research programme: COU-1 monoclonal antibodies - Affitech/NatImmune

Alternative Names: CaOU-1; COU 1; Human monoclonal antibody COU-1

Latest Information Update: 07 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affitech AS; NatImmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Tumour protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Adenocarcinoma; Cancer; Colorectal cancer

Most Recent Events

  • 25 Feb 2005 Antibodies from this programme are available for licensing worldwide (
  • 31 Jul 2002 Preclinical trials in Cancer in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top